Literature DB >> 10360479

Morphometrical characterization of two glioma models in the brain of immunocompetent and immunodeficient rats.

M Saini1, M Bellinzona, F Meyer, G Cali, M Samii.   

Abstract

Although several glioma models exist, systematic morphometrical studies on such experimental tumors are lacking. The purpose of this study was the quantitative assessment of how rat strains, cell lines, injection techniques and location affect tumors reproducibility and histopathological features. Glioma cells were implanted in 3 brain locations, with different injection techniques (free hand, stereotactic, water-tight device), variable volumes, cell concentrations and infusion rates. Tumors were developed from 2 rat glioma cell lines (9L and C6) in immunocompetent (Wistar and Fischer 344) and immunodeficient rats (New Zealand). Animals underwent daily neurological examination. At the scheduled time the tumors were macro and microscopically evaluated and a quantitative morphometrical analysis was performed. C6 gliomas appeared very infiltrative and irregularly shaped; 9L gliomas showed, by using the same injection technique, a grossly regular shape. Margins at the tumor-brain interface were macroscopically demarcated in the immunocompetent rats. In the nude rats, 9L tumors appeared microscopically more infiltrative, although regularly shaped, with a closer morphological resemblance to human gliomas. The implantation in the frontal area, anterior to the nucleus caudatus (3 mm anterior the coronal suture) gave reproducible tumor shape and size, no hydrocephalus and no early neurological deterioration. The use of a stereotactic technique or of a water-tight device, small volume (< 10 microl) of cell suspension, low infusion rate were useful to reduce morbidity and to improve data reproducibility. No difference in morbidity and mortality were observed in immunocompetent and immunodeficient rats. The 9L glioma model with stereotactic implantation constitutes a good option for reliable morphometrical evaluation of tumor growth. We propose a location for tumor implantation anterior to the nucleus caudatus. This produced the longest symptom-free survival.

Entities:  

Mesh:

Year:  1999        PMID: 10360479     DOI: 10.1023/a:1006128825766

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  39 in total

1.  Inhibition of tumor growth in a glioma model treated with boron neutron capture therapy.

Authors:  J H Goodman; J M McGregor; N R Clendenon; R A Gahbauer; R F Barth; A H Soloway; R G Fairchild
Journal:  Neurosurgery       Date:  1990-09       Impact factor: 4.654

2.  Measurements of blood-brain barrier permeability in patients undergoing radiotherapy and chemotherapy for primary cerebral lymphoma.

Authors:  R J Ott; M Brada; M A Flower; J W Babich; S R Cherry; B J Deehan
Journal:  Eur J Cancer       Date:  1991       Impact factor: 9.162

3.  Signal transduction pathways mediating astrocyte IL-6 induction by IL-1 beta and tumor necrosis factor-alpha.

Authors:  J G Norris; L P Tang; S M Sparacio; E N Benveniste
Journal:  J Immunol       Date:  1994-01-15       Impact factor: 5.422

4.  Suramin inhibits glioma cell proliferation in vitro and in the brain.

Authors:  S Takano; S Gately; H Engelhard; A M Tsanaclis; S Brem
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

5.  Correlation between Gd-enhanced MR imaging and histopathology in treated and untreated 9L rat brain tumors.

Authors:  D E Wilkins; G P Raaphorst; J K Saunders; G R Sutherland; I C Smith
Journal:  Magn Reson Imaging       Date:  1995       Impact factor: 2.546

6.  Experimental glioma in primates: a computed tomography model.

Authors:  K G Rieth; G Di Chiro; W T London; J L Sever; S A Houff; P L Kornblith; P E McKeever; C Buonomo; B L Padgett; D L Walker
Journal:  J Comput Assist Tomogr       Date:  1980-06       Impact factor: 1.826

7.  Effects of steroids and nonsteroid anti-inflammatory agents on vascular permeability in a rat glioma model.

Authors:  H R Reichman; C L Farrell; R F Del Maestro
Journal:  J Neurosurg       Date:  1986-08       Impact factor: 5.115

8.  Interstitial taxol delivered from a biodegradable polymer implant against experimental malignant glioma.

Authors:  K A Walter; M A Cahan; A Gur; B Tyler; J Hilton; O M Colvin; P C Burger; A Domb; H Brem
Journal:  Cancer Res       Date:  1994-04-15       Impact factor: 12.701

9.  Endothelial differentiation in intracerebral and subcutaneous experimental gliomas.

Authors:  O Arosarena; C Guerin; H Brem; J Laterra
Journal:  Brain Res       Date:  1994-03-21       Impact factor: 3.252

10.  Paradoxical elevation of Ki-67 labeling with protein kinase inhibition in malignant gliomas.

Authors:  W T Couldwell; M H Weiss; R E Law; D R Hinton
Journal:  J Neurosurg       Date:  1995-03       Impact factor: 5.115

View more
  10 in total

1.  Up-regulation of neuropoiesis generating glial progenitors that infiltrate rat intracranial glioma.

Authors:  Christopher Duntsch; Qihong Zhou; James D Weimar; Bruce Frankel; Jon H Robertson; Tayebeh Pourmotabbed
Journal:  J Neurooncol       Date:  2005-02       Impact factor: 4.130

2.  Correlation of N-cadherin expression in high grade gliomas with tissue invasion.

Authors:  Kenichiro Asano; Christopher D Duntsch; Qihong Zhou; James D Weimar; Dwight Bordelon; Jon H Robertson; Tayebeh Pourmotabbed
Journal:  J Neurooncol       Date:  2004-10       Impact factor: 4.130

3.  Rejection of RG-2 gliomas is mediated by microglia and T lymphocytes.

Authors:  Christopher L Mariani; Joshua G Kouri; Wolfgang J Streit
Journal:  J Neurooncol       Date:  2006-04-13       Impact factor: 4.130

4.  Xenograft transplantation of human malignant astrocytoma cells into immunodeficient rats: an experimental model of glioblastoma.

Authors:  Flávio Key Miura; Maria Jose Ferreira Alves; Mussya Cisotto Rocha; Roseli da Silva; Sueli Mieko Oba-Shinjo; Suely Kazue Nagahashi Marie
Journal:  Clinics (Sao Paulo)       Date:  2010-03       Impact factor: 2.365

5.  In vivo evaluation of intracellular drug-nanocarriers infused into intracranial tumours by convection-enhanced delivery: distribution and radiosensitisation efficacy.

Authors:  Sandrine Vinchon-Petit; Delphine Jarnet; Archibald Paillard; Jean-Pierre Benoit; Emmanuel Garcion; Philippe Menei
Journal:  J Neurooncol       Date:  2009-09-22       Impact factor: 4.130

6.  Characterization of 9L glioma model of the Wistar rat.

Authors:  Maja Stojiljkovic; Vesna Piperski; Mirjana Dacevic; Ljubisav Rakic; Sabera Ruzdijic; Selma Kanazir
Journal:  J Neurooncol       Date:  2003-05       Impact factor: 4.130

7.  Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors.

Authors:  Eilon D Kirson; Vladimír Dbalý; Frantisek Tovarys; Josef Vymazal; Jean F Soustiel; Aviran Itzhaki; Daniel Mordechovich; Shirley Steinberg-Shapira; Zoya Gurvich; Rosa Schneiderman; Yoram Wasserman; Marc Salzberg; Bernhard Ryffel; Dorit Goldsher; Erez Dekel; Yoram Palti
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-05       Impact factor: 11.205

8.  The 9L(LUC)/Wistar rat glioma model is not suitable for immunotherapy.

Authors:  Liping Yang; Jingxiang Zhao; Guihong Zhou; Yunfang Wang; Lusi Li; Hongfeng Yuan; Xue Nan; Lidong Guan; Xuetao Pei
Journal:  Neural Regen Res       Date:  2012-06-25       Impact factor: 5.135

9.  Mitotic Spindle Disruption by Alternating Electric Fields Leads to Improper Chromosome Segregation and Mitotic Catastrophe in Cancer Cells.

Authors:  Moshe Giladi; Rosa S Schneiderman; Tali Voloshin; Yaara Porat; Mijal Munster; Roni Blat; Shay Sherbo; Zeev Bomzon; Noa Urman; Aviran Itzhaki; Shay Cahal; Anna Shteingauz; Aafia Chaudhry; Eilon D Kirson; Uri Weinberg; Yoram Palti
Journal:  Sci Rep       Date:  2015-12-11       Impact factor: 4.379

10.  In vivo detection of c-Met expression in a rat C6 glioma model.

Authors:  R A Towner; N Smith; S Doblas; Y Tesiram; P Garteiser; D Saunders; R Cranford; R Silasi-Mansat; O Herlea; L Ivanciu; D Wu; F Lupu
Journal:  J Cell Mol Med       Date:  2007-01-09       Impact factor: 5.310

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.